[1] Kessler RC,Berglund P,Demler O.The epidemiology of major depressive disorder:results from the national comorbidity survey replication(NCS-R)[J].JAMA, 2003, 89(2): 3095.
[2] Kriston L, von Wolff A, Hlzel L. Effectiveness of psychotherapeutic, pharmacological,and combined treatments for chronic depression: a systematic review[J]. BMC Psychiatry, 2010, 10: 95.
[3] Youdim MB, Weinstock M. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation[J]. Neurotoxicology, 2004, 25(1-2): 243.
[4] 郭 鹏, 丁素菊. 抗抑郁药物临床应用进展[J]. 药学服务与研究, 2009, 9(6): 405.
[5] Tandt H, Audenaert K. SSRIs(selective serotonin reuptake inhibitors) and suicidality in adults, adolescents and children[J]. Tijdschr Psychiatr, 2009, 51(6): 387.
[6] Baldwin D, Woods R. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis[J]. BMJ, 2011, 11: 342.
[7] Mullins CD,Shaya FT.Comparison of first refill rates among users of sertrallne paroxetine, and citalopram[J]. Clin Ther, 2006, 28(2): 297.
[8] Pogosova GV,Zhidko NI.Clinical effectiveness and safety of citalopram in patients with depression after myocardial infarction[J]. Kardiologiia, 2003, 43(1): 24.
[9] Westenberq HG,Sandner C. Tolerability and safety of fluvoxamine and other antidepressants[J]. Int J Clin Pract, 2006, 60(4): 482.
[10] Lundbeck H, Takeda P. Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety[J]. Drugs, 2010, 13(12): 900.
[11] Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials[J]. BMJ, 2010, 341: C4737.
[12] Haine SE,Miljoen HP. Mianserin and ventricular tachycardia: case report and review of the literature[J]. Cardiology, 2006, 106(4): 195.
[13] 朱宇欢.新型抗抑郁药的临床应用[J].中国医院用药评价与分析, 2010, 10(7): 669.
[14] Aurora RN,Zak RS. Best practice guide for the treatment of nightmare disorder in adults[J]. J Clin Sleep Med, 2010, 6(4): 389.
[15] Racagni G, Popoli M. The pharmacological properties of antidepressants[J]. Int Clin Psychopharmacol, 2010, 25(3):117.
[16] Nakayama K. Mechanism of action of new generation antidepressants under development in Japan: focusing on dopamine neurotransmission[J]. Nihon Shinkei Seishin Yakurigaku Zasshi, 2009, 29(3): 99.
[17] 陈瑞玲,赵志刚.抗抑郁症类药物的临床应用研究进展[J].中国临床药理学杂志,2007, 23(1): 54.
[18] Girdler SS, Klatzkin R. Neurosteroids in the context of stress: Implications for depressive disorders[J]. Pharmacol Ther, 2007, 116: 125.
[19] Gavioli EC, Calo'G. Antidepressant-and anxiolytic-like effects of nociceptin/orphanin FQ receptor ligands[J]. Naunyn Schmiedebergs Arch Pharmacol, 2006, 372: 319.
[20] Catena-Dell'Osso M, Bellantuono C. Inflammatory and neurodegenerative pathways in depression: a new avenue for antidepressant development[J]. Curr Med Chem, 2011, 18(2): 245.
[21] Joffe RT. Hormone treatment of depression[J]. Dialogues Clin Neurosci, 2011, 13(1): 127.
[22] Freeman MP,Rapaport MH. Omega-3 fatty acids and depression: from cellular mechanisms to clinical care[J]. J Clin Psychiatry.2011,72(2):258.
[23] Zavoreo I, Basic-Kes V. Post-stroke depression[J]. Acta Clin Croat, 2009, 48(3): 329.
[24] 中国脑血管病防治指南编写委员会.中国脑血管病防治指南[M].北京:人民卫生出版社,2007,102.
[25] Sondor H,Zsolt K.Clinical effectiveness and saftry of paroxetine in post-stroke depression[J]. Orv Hetil, 2006, 147(50): 2397.
[26] Jassrsma T,Johansson P. Quality of life and symptoms of depression in advanced heart failure patients and their partners[J]. Curr Opin Support Palliat Care, 2010, 4(4): 233.
[27] Marc L,Toureche N. Mind-body interventions during pregnancy for preventing or treating women's anxiety[J]. Cochrane Database Syst Rev, 2011, 7: CD007559.
[28] Estrada-Camarena E,Lopez-Rubalcava C. Antidepressant effects of estrogens: a basic approximation[J]. Behav Pharmacol, 2010, 21(5-6): 451.